Albert David formalizes Amit Mahla as Whole-time Director and CEO for 5 years
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Mr. Amit Mahla as Additional Director and Whole-time Director and CEO for 5 years (June 19, 2026 to June 18, 2031), subject to shareholder approval at the 87th AGM. He was already named CEO on May 12, 2026. He has 28 plus years of pharma experience with stints at Cipla, Emcure, Glenmark, Alembic, Sun Pharma, and JB Pharma. Remuneration is fixed till March 31, 2027.
Formalizes an experienced external CEO, signaling leadership continuity and strategic focus for the company.